REMODELING AND REPARATION OF THE CARDIOVASCULAR-SYSTEM

被引:276
作者
WEBER, KT
ANVERSA, P
ARMSTRONG, PW
BRILLA, CG
BURNETT, JC
CRUICKSHANK, JM
DEVEREUX, RB
GILES, TD
KORSGAARD, N
LEIER, CV
MENDELSOHN, FAO
MOTZ, WH
MULVANY, MJ
STRAUER, BE
机构
[1] NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595 USA
[2] ST MICHAELS HOSP, DIV CARDIOL, TORONTO M5B 1W8, ONTARIO, CANADA
[3] MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA
[4] ICI PHARMACEUT PLC, MACCLESFIELD, CHESHIRE, ENGLAND
[5] CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV CARDIOL, NEW YORK, NY 10021 USA
[6] TULANE UNIV, MED CTR, DEPT MED, NEW ORLEANS, LA 70118 USA
[7] AARHUS UNIV, DEPT PHARMACOL, DK-8000 AARHUS, DENMARK
[8] OHIO STATE UNIV, COLL MED, DIV CARDIOL, COLUMBUS, OH 43210 USA
[9] UNIV MELBOURNE, AUSTIN HOSP, DEPT MED, HEIDELBERG, VIC 3084, AUSTRALIA
[10] UNIV DUSSELDORF, DEPT MED, W-4000 DUSSELDORF 1, GERMANY
关键词
D O I
10.1016/0735-1097(92)90130-F
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Growth or altered metabolism of nonmyocyte cells (cardiac fibroblasts, vascular smooth muscle and endothelial cells) alters myocardial and vascular structure (remodeling) and function. However, the precise roles of circulating and locally generated factors such as angiotensin II, aldosterone and endothelin that regulate growth and metabolism of nonmyocyte cells have yet to be fully elucidated. Trials of pharmacologic therapy aimed at preventing structural remodeling and repairing altered myocardial structure to or toward normal in the setting of hypertension, heart failure and diabetes are reviewed. It is proposed that these are therapeutic goals that may reduce cardiovascular morbidity and mortality. Although this hypothesis remains unproved the primary goal of therapy should be to preserve or restore tissue structure and function.
引用
收藏
页码:3 / 16
页数:14
相关论文
共 135 条
  • [31] LEFT-VENTRICULAR SHAPE, AFTERLOAD AND SURVIVAL IN IDIOPATHIC DILATED CARDIOMYOPATHY
    DOUGLAS, PS
    MORROW, R
    IOLI, A
    REICHEK, N
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 13 (02) : 311 - 315
  • [32] ECHOCARDIOGRAPHIC LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSION
    DRAYER, JIM
    GARDIN, JM
    WEBER, MA
    [J]. CHEST, 1983, 84 (02) : 217 - 221
  • [33] DREXLER H, 1991, AM J CARDIOL, V67, pC29
  • [34] LOCALIZATION OF TYPE-I, TYPE-III AND TYPE-IV COLLAGEN MESSENGER-RNAS IN RAT-HEART CELLS BY INSITU HYBRIDIZATION
    EGHBALI, M
    BLUMENFELD, OO
    SEIFTER, S
    BUTTRICK, PM
    LEINWAND, LA
    ROBINSON, TF
    ZERN, MA
    GIAMBRONE, MA
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1989, 21 (01) : 103 - 113
  • [35] CHARACTERIZATION OF CARDIAC ANGIOTENSIN CONVERTING ENZYME (ACE) AND INVIVO INHIBITION FOLLOWING ORAL QUINAPRIL TO RATS
    FABRIS, B
    YAMADA, H
    CUBELA, R
    JACKSON, B
    MENDELSOHN, FAO
    JOHNSTON, CI
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1990, 100 (03) : 651 - 655
  • [36] DIABETIC CARDIOMYOPATHY
    FEIN, FS
    SONNENBLICK, EH
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 1985, 27 (04) : 255 - 270
  • [37] LEFT-VENTRICULAR MASS REDUCTION DURING SALT DEPLETION IN ARTERIAL-HYPERTENSION
    FERRARA, LA
    DESIMONE, G
    PASANISI, F
    MANCINI, M
    MANCINI, M
    [J]. HYPERTENSION, 1984, 6 (05) : 755 - 759
  • [38] PHYSIOLOGICAL-ASPECTS OF PRIMARY HYPERTENSION
    FOLKOW, B
    [J]. PHYSIOLOGICAL REVIEWS, 1982, 62 (02) : 347 - 504
  • [39] COMPARED MYOCARDIAL AND VASCULAR EFFECTS OF CAPTOPRIL AND DIHYDRALAZINE DURING HYPERTENSION DEVELOPMENT IN SPONTANEOUSLY HYPERTENSIVE RATS
    FRESLON, JL
    GIUDICELLI, JF
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1983, 80 (03) : 533 - 543